OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shah on Dosing Tandem Receptor CAR T-Cell Therapy in B-Cell Malignancies

December 3rd 2020

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Dr. Bose on Risk Factors of Essential Thrombocythemia

December 3rd 2020

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.

Dr. Patt on the Role of Sacituzumab Govitecan in TNBC

December 3rd 2020

Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy in triple-negative breast cancer.

Dr. Brody on the Expanding Role of Venetoclax in MCL

December 3rd 2020

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Dr. Rapisuwon on the Frontline Treatment of Acral and Mucosal Melanoma

December 3rd 2020

Suthee Rapisuwon, MD, discusses the frontline treatment of acral and mucosal melanoma.

Dr. Winter on Emerging Agents in CLL

December 3rd 2020

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Dr. Petrylak on the Role of Docetaxel in mHSPC

December 2nd 2020

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Sehgal on Key Targetable Alterations in AML

December 2nd 2020

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.

Dr. Ayers on the Evolving Treatment Landscape in CLL

December 2nd 2020

Emily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

Dr. Hill on the Utility of BTK Inhibitors in Relapsed/Refractory MCL

December 2nd 2020

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Mascarenhas on the Role of Genetic Testing in MPNs

December 2nd 2020

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

Dr. Costello on Considerations for Induction Therapy Selection in Multiple Myeloma

December 2nd 2020

Caitlin Costello, MD, discusses considerations for induction therapy selection in multiple myeloma.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 1st 2020

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. Kim on the Evolution of Therapy in Metastatic HCC

December 1st 2020

Joseph Kim, MD, discusses the evolution of therapy in metastatic hepatocellular carcinoma.

Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL

December 1st 2020

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Agarwal on Unmet Needs in mHSPC

December 1st 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Dr. Weber on the Treatment of LDH-High Melanoma

December 1st 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses the treatment of lactate dehydrogenase (LDH)–high melanoma.

Dr. Winter on the Role of Frontline Targeted Therapies in CLL

November 30th 2020

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the role of frontline targeted therapies in chronic lymphocytic leukemia.

Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

November 30th 2020

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Dr. Ruan on Treatment Considerations for Relapsed/Refractory MCL

November 30th 2020

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.